Program in Pharmacoepidemiology
About the Program
The Program in Pharmacoepidemiology at UCLA advances research on medication safety, effectiveness, and healthcare outcomes through the analysis of large-scale real-world data, helping to improve patient care and inform clinical practice.
Our Research
Through rigorous pharmacoepidemiologic research and advanced data analytics, our program generates evidence that helps shape clinical practice, healthcare policy and patient care.
Our Team
Our multidisciplinary team of researchers, trainees and collaborators advance research on pharmacoepidemiology and improve patient care through evidence-based medicine.
Program News
Research Presented at the International Society for Pharmacoepidemiology 2026 annual meeting in Milan, Italy.
Research Presented at the American Diabetes Association (ADA) 2026 annual meeting in New Orleans, Louisiana.
See Our Publications:
Cardiovascular outcomes of empagliflozin-GLP-1RA combination therapy in type 2 diabetes: EMPRISE study.
This study emulated two comparative effectiveness trials comparing cardiovascular outcomes in patients with Type 2 diabetes who took combinations of various glucose-lowering medications.
Enhancing Evidence Generation by Linking Randomized Clinical Trials to Real-World Data: The INVESTED-Medicare Linkage Study.
This study, funded by the Food and Drug Administration (FDA), evaluated the use of linked clinical trial and Medicare data to validate real-world measures and extend evidence beyond completion of the clinical trial.